Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Breast Cancer
100%
Diseases
44%
Malignant Neoplasm
37%
Overall Survival
37%
Hematopoietic Cell
34%
Cell Transplantation
32%
Tumor
31%
Chemotherapy
27%
Progression Free Survival
25%
Neoplasm
24%
Prostate Cancer
23%
Multiple Myeloma
22%
Cancer
22%
Recurrent Disease
17%
Genetics
16%
Radiation Therapy
16%
Metastatic Breast Cancer
15%
Clinical Trial
15%
Autotransplantation
14%
COVID-19
14%
Hormone Therapy
14%
Pheochromocytoma
14%
Paraganglioma
13%
Immunotherapy
12%
Hepatocellular Carcinoma
12%
Biopsy Technique
12%
Autologous Stem Cell Transplantation
12%
Hazard Ratio
12%
Estrogen Receptor
11%
Mastectomy
10%
Allograft
10%
Diffuse Large B-Cell Lymphoma
10%
Non-Hodgkin Lymphoma
10%
Cancer Therapy
10%
Targeted Therapy
10%
Quality of Life
10%
Oncology
9%
Systemic Therapy
9%
Arm
9%
Mammography
9%
Triple Negative Breast Cancer
9%
Epidermal Growth Factor Receptor
8%
Reduced Intensity Conditioning
8%
Odds Ratio
8%
Neck
8%
Head and Neck Cancer
8%
Myelofibrosis
8%
Colorectal Carcinoma
8%
Biological Marker
8%
Disease Exacerbation
7%
Placebo
7%
Adverse Event
7%
Hodgkin's Lymphoma
7%
Hormone Receptor
7%
Surgeon
7%
Pancreas Cancer
7%
Cancer Mortality
7%
Gemcitabine
7%
Breast Cancer Screening
6%
BRCA1
6%
Pancreas Adenocarcinoma
6%
Chemoradiotherapy
6%
Elacestrant
6%
Autologous Hematopoietic Stem Cell Transplantation
6%
Cohort Analysis
6%
Oral
6%
Clear Cell Renal Cell Carcinoma
6%
Pediatrics
5%
Genetic Screening
5%
Neoadjuvant Chemotherapy
5%
Squamous Cell Carcinoma
5%
Overdiagnosis
5%
Multivariate Analysis
5%
Contralateral
5%
Disease Free Survival
5%
Quadrantectomy
5%
Survival Rate
5%
Axillary Lymph Node
5%
Glioblastoma
5%
Metastatic Carcinoma
5%
Median Follow Up
5%
Cisplatin
5%
Prognostic Factor
5%
Radioembolization
5%
Autograft
5%
Systematic Review
5%
Acute Myeloid Leukemia
5%
Hematopoietic Stem Cell Transplantation
5%
Follicular Lymphoma
5%
Infection
5%
Clinician
5%
Breast Disease
5%
Cholangiocarcinoma
5%
Pembrolizumab
5%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
33%
Neoplasm
26%
Malignant Neoplasm
26%
Diseases
23%
Chemotherapy Regimens
18%
Solid Malignant Neoplasm
16%
Clinical Trial
15%
Prostate Cancer
14%
Overall Survival
14%
Progression Free Survival
13%
Adverse Event
13%
Immunotherapy
10%
Glioblastoma
10%
Pharmacokinetics
9%
Metastatic Breast Cancer
9%
Carcinogenesis
8%
Pancreas Adenocarcinoma
8%
Triple Negative Breast Cancer
8%
Multiple Myeloma
8%
Antitumor Activity
8%
Estrogen Receptor
8%
Paclitaxel
8%
Head and Neck Cancer
7%
Pancreas Cancer
7%
Pembrolizumab
7%
Biological Marker
7%
Histone Deacetylase Inhibitor
7%
Placebo
7%
Liver Cell Carcinoma
6%
Cisplatin
6%
Anticarcinogen
6%
Epidermal Growth Factor Receptor
6%
Recurrent Disease
6%
Gemcitabine
6%
Endocrine Therapy
6%
Vorinostat
6%
Bevacizumab
5%
Acute Myeloid Leukemia
5%
Melanoma
5%
Ruxolitinib
5%
Pelareorep
5%
Biochemistry, Genetics and Molecular Biology
Cancer Cell
12%
Programmed Cell Death
12%
Carcinogenesis
11%
Genomics
11%
Homologous Recombination
10%
Proteolysis
9%
BRCA1
9%
Autophagy
7%
Estrogen Receptor
6%
Myeloid
6%
Progression Free Survival
6%
Transcription
6%
Clinical Trial
6%
Germ Cell
6%
Overall Survival
6%
Tumor Suppressor Protein
6%
Genetics
5%
Germline
5%
DNA Repair
5%
Targeted Therapy
5%
Gene Mutation
5%